Richard W. L. Ridley

Array ( [id] => 19387864 [patent_doc_number] => 20240277734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => COMPOSITION COMPRISING LIPOIC ACID AND VITAMIN D FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES AND PERIPHERAL NEUROPATHIES [patent_app_type] => utility [patent_app_number] => 18/646365 [patent_app_country] => US [patent_app_date] => 2024-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12748 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18646365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379252 [patent_doc_number] => 20240269122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => NASAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/638204 [patent_app_country] => US [patent_app_date] => 2024-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20401229 [patent_doc_number] => 12491189 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => OTIC formulations, methods and devices [patent_app_type] => utility [patent_app_number] => 18/638340 [patent_app_country] => US [patent_app_date] => 2024-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1779 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19360791 [patent_doc_number] => 20240262825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => PAIN TREATING COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/602482 [patent_app_country] => US [patent_app_date] => 2024-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9977 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18602482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19263511 [patent_doc_number] => 20240207208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => Treatments for Diabetes Mellitus and Obesity [patent_app_type] => utility [patent_app_number] => 18/599902 [patent_app_country] => US [patent_app_date] => 2024-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18599902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543085 [patent_doc_number] => 20240360121 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => GLS1 INHIBITORS FOR TREATING DISEASE [patent_app_type] => utility [patent_app_number] => 18/597265 [patent_app_country] => US [patent_app_date] => 2024-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18597265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332482 [patent_doc_number] => 20240246912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => CRYSTALLINE SALTS OF PSILOCIN [patent_app_type] => utility [patent_app_number] => 18/591925 [patent_app_country] => US [patent_app_date] => 2024-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18591925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248558 [patent_doc_number] => 20240199545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => CRYSTALLINE SALTS OF PSILOCIN [patent_app_type] => utility [patent_app_number] => 18/591969 [patent_app_country] => US [patent_app_date] => 2024-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18591969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19359270 [patent_doc_number] => 20240261304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => TERPENE-ENRICHED CANNABINOID COMPOSITION FOR TREATING CONDITIONS AND/ OR SYMPTOMS ASSOCIATED WITH A STRESSFUL EVENT [patent_app_type] => utility [patent_app_number] => 18/441254 [patent_app_country] => US [patent_app_date] => 2024-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19707767 [patent_doc_number] => 20250017909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO HYDROGEN SULFIDE [patent_app_type] => utility [patent_app_number] => 18/441087 [patent_app_country] => US [patent_app_date] => 2024-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6485 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343512 [patent_doc_number] => 20240252475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => TIOTROPIUM COMBINATION PRODUCT COMPOSITIONS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 18/423281 [patent_app_country] => US [patent_app_date] => 2024-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 102274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18423281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417254 [patent_doc_number] => 20240293377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO [patent_app_type] => utility [patent_app_number] => 18/409703 [patent_app_country] => US [patent_app_date] => 2024-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 314 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18409703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19613118 [patent_doc_number] => 20240398798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS [patent_app_type] => utility [patent_app_number] => 18/407729 [patent_app_country] => US [patent_app_date] => 2024-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18407729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20433234 [patent_doc_number] => 12503458 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-23 [patent_title] => 5-hydroxytryptamine receptor 7 activity modulators and their method of use [patent_app_type] => utility [patent_app_number] => 18/544952 [patent_app_country] => US [patent_app_date] => 2023-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27870 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18544952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19359211 [patent_doc_number] => 20240261245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY [patent_app_type] => utility [patent_app_number] => 18/530612 [patent_app_country] => US [patent_app_date] => 2023-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18530612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19473839 [patent_doc_number] => 12103915 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => TEAD inhibitors and methods of uses thereof [patent_app_type] => utility [patent_app_number] => 18/529689 [patent_app_country] => US [patent_app_date] => 2023-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49481 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18529689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19279849 [patent_doc_number] => 20240216321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => FERMENTATIVELY-PRODUCED RETINOID CONTAINING COMPOSITIONS, AND THE METHDOS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/527530 [patent_app_country] => US [patent_app_date] => 2023-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23078 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18527530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20714197 [patent_doc_number] => 12629421 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-19 [patent_title] => Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid [patent_app_type] => utility [patent_app_number] => 18/506138 [patent_app_country] => US [patent_app_date] => 2023-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 184 [patent_figures_cnt] => 368 [patent_no_of_words] => 11050 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 249 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18506138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018869 [patent_doc_number] => 20240075040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS [patent_app_type] => utility [patent_app_number] => 18/500214 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281488 [patent_doc_number] => 20240217962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/486668 [patent_app_country] => US [patent_app_date] => 2023-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 158787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18486668 [rel_patent_id] =>[rel_patent_doc_number] =>)